Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens.
Wilson EM, Kattakuzhy S, Sidharthan S, Sims Z, Tang L, McLaughlin M, Price A, Nelson A, Silk R, Gross C, Akoth E, Mo H, Subramanian GM, Pang PS, McHutchison JG, Osinusi A, Masur H, Kohli A, Kottilil S. Wilson EM, et al. Among authors: silk r. Clin Infect Dis. 2016 Feb 1;62(3):280-288. doi: 10.1093/cid/civ874. Epub 2015 Oct 31. Clin Infect Dis. 2016. PMID: 26521268 Free PMC article. Clinical Trial.
Effect of HIV on liver fibrosis among HCV-infected African Americans.
Silver D, Karnik G, Osinusi A, Silk R, Stabinski L, Doonquah L, Henn S, Teferi G, Masur H, Kottilil S, Fishbein D. Silver D, et al. Among authors: silk r. Clin Infect Dis. 2013 May;56(9):1280-3. doi: 10.1093/cid/cit037. Epub 2013 Feb 1. Clin Infect Dis. 2013. PMID: 23378283 Free PMC article.
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.
Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, Sneller M, Kohli A, Barrett L, Proschan M, Herrmann E, Shivakumar B, Gu W, Kwan R, Teferi G, Talwani R, Silk R, Kotb C, Wroblewski S, Fishbein D, Dewar R, Highbarger H, Zhang X, Kleiner D, Wood BJ, Chavez J, Symonds WT, Subramanian M, McHutchison J, Polis MA, Fauci AS, Masur H, Kottilil S. Osinusi A, et al. Among authors: silk r. JAMA. 2013 Aug 28;310(8):804-11. doi: 10.1001/jama.2013.109309. JAMA. 2013. PMID: 23982366 Free PMC article. Clinical Trial.
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.
Kohli A, Osinusi A, Sims Z, Nelson A, Meissner EG, Barrett LL, Bon D, Marti MM, Silk R, Kotb C, Gross C, Jolley TA, Sidharthan S, Petersen T, Townsend K, Egerson D, Kapoor R, Spurlin E, Sneller M, Proschan M, Herrmann E, Kwan R, Teferi G, Talwani R, Diaz G, Kleiner DE, Wood BJ, Chavez J, Abbott S, Symonds WT, Subramanian GM, Pang PS, McHutchison J, Polis MA, Fauci AS, Masur H, Kottilil S. Kohli A, et al. Among authors: silk r. Lancet. 2015 Mar 21;385(9973):1107-13. doi: 10.1016/S0140-6736(14)61228-9. Epub 2015 Jan 13. Lancet. 2015. PMID: 25591505 Free PMC article. Clinical Trial.
Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.
Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, Bon D, Silk R, Gross C, Price A, Sajadi M, Sidharthan S, Sims Z, Herrmann E, Hogan J, Teferi G, Talwani R, Proschan M, Jenkins V, Kleiner DE, Wood BJ, Subramanian GM, Pang PS, McHutchison JG, Polis MA, Fauci AS, Masur H, Kottilil S. Osinusi A, et al. Among authors: silk r. JAMA. 2015 Mar 24-31;313(12):1232-9. doi: 10.1001/jama.2015.1373. JAMA. 2015. PMID: 25706232 Free PMC article. Clinical Trial.
Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.
Kohli A, Kapoor R, Sims Z, Nelson A, Sidharthan S, Lam B, Silk R, Kotb C, Gross C, Teferi G, Sugarman K, Pang PS, Osinusi A, Polis MA, Rustgi V, Masur H, Kottilil S. Kohli A, et al. Among authors: silk r. Lancet Infect Dis. 2015 Sep;15(9):1049-1054. doi: 10.1016/S1473-3099(15)00157-7. Epub 2015 Jul 14. Lancet Infect Dis. 2015. PMID: 26187031 Free PMC article. Clinical Trial.
Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease.
Kattakuzhy S, Wilson E, Sidharthan S, Sims Z, McLaughlin M, Price A, Silk R, Gross C, Akoth E, McManus M, Emmanuel B, Shrivastava S, Tang L, Nelson A, Teferi G, Chavez J, Lam B, Mo H, Osinusi A, Polis MA, Masur H, Kohli A, Kottilil S. Kattakuzhy S, et al. Among authors: silk r. Clin Infect Dis. 2016 Feb 15;62(4):440-447. doi: 10.1093/cid/civ897. Epub 2015 Oct 26. Clin Infect Dis. 2016. PMID: 26503379 Free PMC article. Clinical Trial.
Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.
Kohli A, Kattakuzhy S, Sidharthan S, Nelson A, McLaughlin M, Seamon C, Wilson E, Meissner EG, Sims Z, Silk R, Gross C, Akoth E, Tang L, Price A, Jolley TA, Emmanuel B, Proschan M, Teferi G, Chavez J, Abbott S, Osinusi A, Mo H, Polis MA, Masur H, Kottilil S. Kohli A, et al. Among authors: silk r. Ann Intern Med. 2015 Dec 15;163(12):899-907. doi: 10.7326/M15-0642. Epub 2015 Nov 24. Ann Intern Med. 2015. PMID: 26595450 Free PMC article. Clinical Trial.
High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study.
Petersen T, Townsend K, Gordon LA, Sidharthan S, Silk R, Nelson A, Gross C, Calderón M, Proschan M, Osinusi A, Polis MA, Masur H, Kottilil S, Kohli A. Petersen T, et al. Among authors: silk r. Hepatol Int. 2016 Mar;10(2):310-9. doi: 10.1007/s12072-015-9680-7. Epub 2015 Nov 26. Hepatol Int. 2016. PMID: 26612014 Free PMC article. Clinical Trial.
40 results